Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.

Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM.

Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19. Review.

PMID:
29145974
2.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

3.

Perioperative hypothermia in neonatal intensive care unit patients: effectiveness of a thermoregulation intervention and associated risk factors.

Engorn BM, Kahntroff SL, Frank KM, Singh S, Harvey HA, Barkulis CT, Barnett AM, Olambiwonnu OO, Heitmiller ES, Greenberg RS.

Paediatr Anaesth. 2017 Feb;27(2):196-204. doi: 10.1111/pan.13047. Epub 2016 Dec 5.

PMID:
27917566
4.

Primary female breast sarcoma: clinicopathological features, treatment and prognosis.

Yin M, Mackley HB, Drabick JJ, Harvey HA.

Sci Rep. 2016 Aug 11;6:31497. doi: 10.1038/srep31497.

5.

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.

Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ.

Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6. Review.

6.

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.

7.

Endoscopic ultrasound-guided ethanol ablation of a large metastatic carcinoid tumor: success with a note of caution.

Mathers BW, Harvey HA, Dye CE, Dougherty-Hamod B, Moyer MT.

Endosc Int Open. 2014 Dec;2(4):E256-8. doi: 10.1055/s-0034-1377612. Epub 2014 Sep 19.

8.

Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.

Kline CL, Schiccitano A, Zhu J, Beachler C, Sheikh H, Harvey HA, Mackley HB, McKenna K, Staveley-O'Carroll K, Poritz L, Messaris E, Stewart D, Sivik J, El-Deiry WS.

Clin Colorectal Cancer. 2014 Jun;13(2):119-26. doi: 10.1016/j.clcc.2013.11.001. Epub 2013 Nov 20.

PMID:
24461492
9.

Predicting therapy response in live tumor cells isolated with the flexible micro spring array device.

Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, Yang Z, Harvey HA, Cream LV, Kumar SM, Robertson GP, Zheng S, Drabick JJ, Truica CI, El-Deiry WS.

Cell Cycle. 2013 Jul 1;12(13):2132-43. doi: 10.4161/cc.25165. Epub 2013 Jun 11.

10.

Update on clinical trials: genetic targets in breast cancer.

Lim B, Cream LV, Harvey HA.

Adv Exp Med Biol. 2013;779:35-54. doi: 10.1007/978-1-4614-6176-0_2. Review.

PMID:
23288634
11.

Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting.

Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS.

J Clin Oncol. 2011 Jul 20;29(21):2946-7; author reply 2947-8. doi: 10.1200/JCO.2011.36.6179. Epub 2011 Jun 20. No abstract available.

PMID:
21690466
12.

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment.

Deshaies I, Cherenfant J, Gusani NJ, Jiang Y, Harvey HA, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF.

Ther Clin Risk Manag. 2010 Oct 5;6:453-8. doi: 10.2147/TCRM.S5634.

13.

The 1918 influenza pandemic: lessons for 2009 and the future.

Morens DM, Taubenberger JK, Harvey HA, Memoli MJ.

Crit Care Med. 2010 Apr;38(4 Suppl):e10-20. doi: 10.1097/CCM.0b013e3181ceb25b. Review.

14.

Biology of bone metastases: causes and consequences.

Harvey HA, Cream Lv.

Clin Breast Cancer. 2007 Jul;7 Suppl 1:S7-S13. Review.

PMID:
17683652
15.

Hypercalcemia and gallium nitrate.

Harvey HA, Almokadem SM.

J Support Oncol. 2004 Nov-Dec;2(6):516-7. No abstract available.

PMID:
16329217
16.

Toremifene: an evaluation of its safety profile.

Harvey HA, Kimura M, Hajba A.

Breast. 2006 Apr;15(2):142-57. Epub 2005 Nov 9. Review.

PMID:
16289904
17.

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W.

Cancer. 2005 Jul 15;104(2):257-63.

18.

Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.

Harvey HA.

Semin Oncol. 2004 Dec;31(6 Suppl 12):23-30. Review.

PMID:
15719598
19.

Treatment of advanced pancreatic cancer with opioid growth factor: phase I.

Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS.

Anticancer Drugs. 2004 Mar;15(3):203-9.

PMID:
15014352
20.

Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.

Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J, Lipton A.

Ann Oncol. 2004 Mar;15(3):455-9.

PMID:
14998848
21.

Metastatic breast cancer: overview of treatment.

Ali SM, Harvey HA, Lipton A.

Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S132-7. Review.

PMID:
14600603
22.

Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.

Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W.

J Clin Oncol. 2003 May 15;21(10):1967-72.

PMID:
12743150
24.

Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.

Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A.

Clin Chem. 2002 Aug;48(8):1314-20.

25.

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J.

J Clin Oncol. 2002 Mar 15;20(6):1467-72.

PMID:
11896093
26.
27.
28.

Modulation of gonococcal piliation by regulatable transcription of pilE.

Long CD, Hayes SF, van Putten JP, Harvey HA, Apicella MA, Seifert HS.

J Bacteriol. 2001 Mar;183(5):1600-9.

29.

Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm.

Harvey HA, Porat N, Campbell CA, Jennings M, Gibson BW, Phillips NJ, Apicella MA, Blake MS.

Mol Microbiol. 2000 Jun;36(5):1059-70.

30.

Use of aromatase inhibitors in breast carcinoma.

Santen RJ, Harvey HA.

Endocr Relat Cancer. 1999 Mar;6(1):75-92. Review.

PMID:
10732791
31.

Macropinocytosis as a mechanism of entry into primary human urethral epithelial cells by Neisseria gonorrhoeae.

Zenni MK, Giardina PC, Harvey HA, Shao J, Ketterer MR, Lubaroff DM, Williams RD, Apicella MA.

Infect Immun. 2000 Mar;68(3):1696-9.

32.

Combined chemoradiotherapy for unresectable pancreatic cancer.

Martin JL, Harvey HA, Lipton A, Martin R.

Am J Clin Oncol. 1999 Jun;22(3):309-14.

PMID:
10362344
33.

Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.

Costa LA, Kopreski MS, Demers LM, Chinchilli VM, Santen RJ, Harvey HA, Lipton A.

Cancer. 1999 Jan 1;85(1):100-3.

PMID:
9921980
34.

Emerging role of aromatase inhibitors in the treatment of breast cancer.

Harvey HA.

Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):32-5. Review.

35.
36.

Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.

Eskander ED, Harvey HA, Givant E, Lipton A.

Am J Clin Oncol. 1997 Oct;20(5):511-4.

PMID:
9345339
37.

Ultrastructural analysis of primary human urethral epithelial cell cultures infected with Neisseria gonorrhoeae.

Harvey HA, Ketterer MR, Preston A, Lubaroff D, Williams R, Apicella MA.

Infect Immun. 1997 Jun;65(6):2420-7.

38.

The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment.

Hopper KD, Kasales CJ, Eggli KD, TenHave TR, Belman NM, Potok PS, Van Slyke MA, Olt GJ, Close P, Lipton A, Harvey HA, Hartzel JS.

J Comput Assist Tomogr. 1996 Nov-Dec;20(6):930-7.

PMID:
8933793
39.

Aromatase inhibitors in clinical practice: current status and a look to the future.

Harvey HA.

Semin Oncol. 1996 Aug;23(4 Suppl 9):33-8. Review.

PMID:
8824463
40.

The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.

Harvey HA, Lipton A.

Support Care Cancer. 1996 May;4(3):213-7.

PMID:
8739655
41.

Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma.

Belman N, Bonnem EM, Harvey HA, Lipton A.

Invest New Drugs. 1996;14(4):387-9.

PMID:
9157074
42.

Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.

Kopreski MS, Lipton A, Harvey HA, Kumar R.

Anticancer Res. 1996 Jan-Feb;16(1):433-6.

PMID:
8615649
43.

Epidermal growth factor receptor ectodomain in the urine of patients with squamous cell carcinoma.

Witters LM, Curley EM, Kumar R, Chinchilli VM, Harvey JP, Crebbin V, Harvey HA, Lipton A.

Clin Cancer Res. 1995 May;1(5):551-7.

44.

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.

Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adlercruetz H, Trunet PF, Santen RJ.

Cancer. 1995 Apr 15;75(8):2132-8.

PMID:
7697604
45.

The management of hypercalcemia of malignancy.

Harvey HA.

Support Care Cancer. 1995 Mar;3(2):123-9. Review.

PMID:
7773580
46.

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.

Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C, Santen RJ.

J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):687-91.

PMID:
8476785
47.

The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.

Demers LM, Lipton A, Harvey HA, Hanagan J, Mulagha M, Santen RJ.

J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):683-5.

PMID:
8386541
48.

Prognostic value of breast cancer aromatase.

Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews YL.

Cancer. 1992 Oct 1;70(7):1951-5.

PMID:
1525771
49.

A decision-theoretic evaluation of early stopping rules.

Heitjan DF, Houts PS, Harvey HA.

Stat Med. 1992 Mar;11(5):673-83.

PMID:
1594809
50.

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.

Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA.

J Clin Oncol. 1991 Jul;9(7):1151-6.

PMID:
2045856

Supplemental Content

Loading ...
Support Center